JP2014524744A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524744A5 JP2014524744A5 JP2014520368A JP2014520368A JP2014524744A5 JP 2014524744 A5 JP2014524744 A5 JP 2014524744A5 JP 2014520368 A JP2014520368 A JP 2014520368A JP 2014520368 A JP2014520368 A JP 2014520368A JP 2014524744 A5 JP2014524744 A5 JP 2014524744A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- acid sequence
- amino acid
- folate receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000010451 Folate receptor alpha Human genes 0.000 claims 54
- 108050001931 Folate receptor alpha Proteins 0.000 claims 54
- 125000003275 alpha amino acid group Chemical group 0.000 claims 48
- 239000000427 antigen Substances 0.000 claims 38
- 102000036639 antigens Human genes 0.000 claims 38
- 108091007433 antigens Proteins 0.000 claims 38
- 239000012634 fragment Substances 0.000 claims 38
- 102100035139 Folate receptor alpha Human genes 0.000 claims 37
- 238000000034 method Methods 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 16
- 239000012472 biological sample Substances 0.000 claims 12
- 239000000523 sample Substances 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- 208000009956 adenocarcinoma Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 claims 2
- 239000007850 fluorescent dye Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 229960003330 pentetic acid Drugs 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000003040 circulating cell Anatomy 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 102000006815 folate receptor Human genes 0.000 claims 1
- 108020005243 folate receptor Proteins 0.000 claims 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 229910052707 ruthenium Inorganic materials 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161508444P | 2011-07-15 | 2011-07-15 | |
| US61/508,444 | 2011-07-15 | ||
| US201261604412P | 2012-02-28 | 2012-02-28 | |
| US61/604,412 | 2012-02-28 | ||
| US201261604954P | 2012-02-29 | 2012-02-29 | |
| US61/604,954 | 2012-02-29 | ||
| PCT/US2012/046672 WO2013012722A1 (en) | 2011-07-15 | 2012-07-13 | Anti-folate receptor alpha antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017190224A Division JP6526143B2 (ja) | 2011-07-15 | 2017-09-29 | 抗葉酸受容体アルファ抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524744A JP2014524744A (ja) | 2014-09-25 |
| JP2014524744A5 true JP2014524744A5 (enExample) | 2015-08-06 |
| JP6220333B2 JP6220333B2 (ja) | 2017-10-25 |
Family
ID=46516898
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520368A Active JP6220333B2 (ja) | 2011-07-15 | 2012-07-13 | 抗葉酸受容体アルファ抗体およびその使用 |
| JP2017190224A Active JP6526143B2 (ja) | 2011-07-15 | 2017-09-29 | 抗葉酸受容体アルファ抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017190224A Active JP6526143B2 (ja) | 2011-07-15 | 2017-09-29 | 抗葉酸受容体アルファ抗体およびその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US8475795B2 (enExample) |
| EP (2) | EP2731972B1 (enExample) |
| JP (2) | JP6220333B2 (enExample) |
| CN (2) | CN107011439B (enExample) |
| AU (3) | AU2012284321C1 (enExample) |
| BR (1) | BR112014001030A2 (enExample) |
| CA (1) | CA2841725C (enExample) |
| CY (1) | CY1120600T1 (enExample) |
| DK (1) | DK2731972T3 (enExample) |
| ES (2) | ES2824498T3 (enExample) |
| HR (1) | HRP20180353T1 (enExample) |
| HU (1) | HUE036929T2 (enExample) |
| LT (1) | LT2731972T (enExample) |
| PL (1) | PL2731972T3 (enExample) |
| PT (1) | PT2731972T (enExample) |
| RS (1) | RS56985B1 (enExample) |
| SG (1) | SG10201605278PA (enExample) |
| SI (1) | SI2731972T1 (enExample) |
| SM (1) | SMT201800150T1 (enExample) |
| TR (1) | TR201802838T4 (enExample) |
| WO (1) | WO2013012722A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3196212B1 (en) | 2010-02-24 | 2020-06-03 | ImmunoGen, Inc. | Immunoconjugates comprising a folate receptor 1 antibody |
| UA113403C2 (xx) | 2011-04-01 | 2017-01-25 | Спосіб підвищення ефективності folr1 терапії раку | |
| JP6220333B2 (ja) * | 2011-07-15 | 2017-10-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗葉酸受容体アルファ抗体およびその使用 |
| SMT202000158T1 (it) | 2012-08-31 | 2020-05-08 | Immunogen Inc | Saggi e kit diagnostici per il rilevamento del recettore dei folati 1 |
| US20160311921A1 (en) | 2013-06-20 | 2016-10-27 | Morphotek ,Inc. | Methods for treatment of ovarian cancer |
| CA2921975C (en) | 2013-08-30 | 2024-02-13 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| CN106415269B (zh) * | 2014-05-08 | 2020-11-27 | 贵州美鑫达医疗科技有限公司 | 直接免疫组织化学测定 |
| EP3221355B1 (en) | 2014-11-20 | 2020-10-07 | F.Hoffmann-La Roche Ag | Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| DK3221357T3 (da) | 2014-11-20 | 2020-08-10 | Hoffmann La Roche | Fælles letkæder og fremgangsmåder til anvendelse |
| EA201791121A1 (ru) | 2014-11-20 | 2018-04-30 | Ф. Хоффманн-Ля Рош Аг | Активирующие т-клетки биспецифические антигенсвязывающие молекулы против folri и cd3 |
| SG11201708546UA (en) * | 2015-04-17 | 2017-11-29 | Morphotek Inc | Methods for treating lung cancer |
| US10172875B2 (en) | 2015-09-17 | 2019-01-08 | Immunogen, Inc. | Therapeutic combinations comprising anti-FOLR1 immunoconjugates |
| AU2017308159B2 (en) | 2016-08-12 | 2023-08-10 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| WO2018031968A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| US10822410B2 (en) | 2016-11-23 | 2020-11-03 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| CN107353325B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽1及其应用 |
| CN107793471B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽4及其应用 |
| CN107446021B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽5及其应用 |
| CN107446020B (zh) * | 2017-07-28 | 2019-10-01 | 中国药科大学 | 叶酸受体α特异性结合肽2及其应用 |
| EP3679371A4 (en) * | 2017-09-05 | 2021-06-16 | Immunogen, Inc. | METHOD OF DETECTING FOLATE RECEPTOR 1 IN A PATIENT SAMPLE |
| CN111936146A (zh) | 2018-02-07 | 2020-11-13 | L.E.A.F.控股集团公司 | α聚谷氨酸化四氢叶酸及其用途 |
| US11730738B2 (en) | 2018-02-07 | 2023-08-22 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| US12076402B2 (en) | 2018-02-07 | 2024-09-03 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| CA3090509A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated methotrexate and uses thereof |
| CA3090389A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| US12246019B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| CA3090384A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| WO2019157140A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| WO2019157145A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
| US11779584B2 (en) | 2018-02-07 | 2023-10-10 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pemetrexed and uses thereof |
| CA3090875A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| EP3752158A4 (en) | 2018-02-14 | 2022-03-09 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF |
| JP7462950B2 (ja) | 2018-02-14 | 2024-04-08 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | ガンマポリグルタミン酸化メトトレキセートおよびその使用 |
| CN111971047A (zh) | 2018-02-14 | 2020-11-20 | L.E.A.F.控股集团公司 | γ聚谷氨酸化四氢叶酸及其用途 |
| CA3090753A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| US11873335B2 (en) | 2018-03-13 | 2024-01-16 | Phanes Therapeutics, Inc. | Anti-folate receptor 1 antibodies and uses thereof |
| KR102275930B1 (ko) | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Folr1에 특이적으로 결합하는 항체 및 그의 용도 |
| WO2020016661A2 (en) * | 2018-07-09 | 2020-01-23 | Multitude Inc. | Antibodies specific to folate receptor alpha |
| CN111393528B (zh) * | 2020-01-19 | 2023-01-31 | 中国药科大学 | 一种靶向叶酸受体α的单链抗体及其应用 |
| US20230210989A1 (en) * | 2020-06-03 | 2023-07-06 | Kar Muthumani | Monoclonal Antibody Against Human Siglec-9 and Use For Immunotherapy |
| WO2022256507A1 (en) * | 2021-06-04 | 2022-12-08 | Immunogen, Inc. | Treatment of cancer in patients with soluble fr-alpha |
| WO2023009529A2 (en) | 2021-07-28 | 2023-02-02 | Trustees Of Boston University | Novel polypeptides and uses thereof |
| CN118047871A (zh) * | 2022-11-16 | 2024-05-17 | 迈威(上海)生物科技股份有限公司 | 一种靶向FRα的抗体或其抗原结合片段及其应用 |
| UY40783A (es) | 2023-06-12 | 2024-12-31 | Amgen Inc | Proteínas de unión a agonistas del receptor beta de linfotoxina |
| CN117700557B (zh) * | 2024-02-05 | 2024-04-30 | 卡秋(江苏)生物科技有限公司 | 一种特异性结合叶酸受体α的抗体或抗原结合片段 |
| CN117700556B (zh) * | 2024-02-05 | 2024-04-12 | 苏州百道医疗科技有限公司 | 一种抗FRα小鼠单克隆抗体及其应用 |
| CN120554514B (zh) * | 2025-07-29 | 2025-12-05 | 合肥综合性国家科学中心大健康研究院 | 一种靶向人的叶酸受体α的单克隆抗体 |
| CN120842412B (zh) * | 2025-09-23 | 2025-12-05 | 合肥综合性国家科学中心大健康研究院 | 一种靶向人的叶酸受体α的单克隆抗体及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6770445B1 (en) | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
| US7270960B2 (en) | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| US20080131366A1 (en) | 2003-03-17 | 2008-06-05 | Manohar Ratnam | Folate Receptor Gene Modulation For Cancer Diagnosis And Therapy |
| US20040235108A1 (en) | 2003-05-23 | 2004-11-25 | Luigi Grasso | Monoclonal antibodies that specifically bind a tumor antigen |
| EP2316857A1 (en) | 2004-02-12 | 2011-05-04 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| US20090081710A1 (en) | 2005-03-30 | 2009-03-26 | Purdue Research Foundation | Method for Cancer Prognosis Using Cellular Folate Vitamin Receptor Quantification |
| US20060239910A1 (en) | 2005-04-22 | 2006-10-26 | Morphotek Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| EP1900752A1 (en) | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| US7754698B2 (en) | 2007-01-09 | 2010-07-13 | Isis Pharmaceuticals, Inc. | Modulation of FR-alpha expression |
| FR2918994B1 (fr) | 2007-07-20 | 2012-10-19 | Rhodia Operations | Formulations de diesters d'acide carboxylique et leur utilisation pour le traitement de materiaux. |
| WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
| US20110177525A1 (en) | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
| MX368394B (es) | 2010-11-05 | 2019-10-01 | Eisai Inc | Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato. |
| EP2680839A1 (en) | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| JP6220333B2 (ja) * | 2011-07-15 | 2017-10-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗葉酸受容体アルファ抗体およびその使用 |
-
2012
- 2012-07-13 JP JP2014520368A patent/JP6220333B2/ja active Active
- 2012-07-13 BR BR112014001030A patent/BR112014001030A2/pt not_active Application Discontinuation
- 2012-07-13 LT LTEP12736054.3T patent/LT2731972T/lt unknown
- 2012-07-13 SM SM20180150T patent/SMT201800150T1/it unknown
- 2012-07-13 PL PL12736054T patent/PL2731972T3/pl unknown
- 2012-07-13 AU AU2012284321A patent/AU2012284321C1/en active Active
- 2012-07-13 WO PCT/US2012/046672 patent/WO2013012722A1/en not_active Ceased
- 2012-07-13 RS RS20180252A patent/RS56985B1/sr unknown
- 2012-07-13 PT PT127360543T patent/PT2731972T/pt unknown
- 2012-07-13 CA CA2841725A patent/CA2841725C/en active Active
- 2012-07-13 SI SI201231234T patent/SI2731972T1/en unknown
- 2012-07-13 SG SG10201605278PA patent/SG10201605278PA/en unknown
- 2012-07-13 CN CN201611025725.1A patent/CN107011439B/zh active Active
- 2012-07-13 US US13/548,775 patent/US8475795B2/en active Active
- 2012-07-13 DK DK12736054.3T patent/DK2731972T3/en active
- 2012-07-13 HR HRP20180353TT patent/HRP20180353T1/hr unknown
- 2012-07-13 HU HUE12736054A patent/HUE036929T2/hu unknown
- 2012-07-13 CN CN201280043606.2A patent/CN103998467B/zh active Active
- 2012-07-13 ES ES17196948T patent/ES2824498T3/es active Active
- 2012-07-13 EP EP12736054.3A patent/EP2731972B1/en active Active
- 2012-07-13 EP EP17196948.8A patent/EP3330291B1/en active Active
- 2012-07-13 ES ES12736054.3T patent/ES2663556T3/es active Active
- 2012-07-13 TR TR2018/02838T patent/TR201802838T4/tr unknown
-
2013
- 2013-03-13 US US13/800,575 patent/US8834877B2/en active Active
-
2014
- 2014-08-04 US US14/451,044 patent/US9599621B2/en active Active
-
2017
- 2017-02-16 US US15/434,326 patent/US10101343B2/en active Active
- 2017-04-11 AU AU2017202365A patent/AU2017202365B2/en active Active
- 2017-09-29 JP JP2017190224A patent/JP6526143B2/ja active Active
-
2018
- 2018-03-01 CY CY181100260T patent/CY1120600T1/el unknown
- 2018-09-26 AU AU2018236755A patent/AU2018236755B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524744A5 (enExample) | ||
| HRP20180353T1 (hr) | Protutijela protiv folatnog receptora alfa i njihova upotreba | |
| US20200200753A1 (en) | Methods and kits for detecting prostate cancer biomarkers | |
| JP6075881B2 (ja) | 乳癌のバイオマーカー | |
| JP2020510409A5 (enExample) | ||
| JP2015533788A5 (enExample) | ||
| JP2013508736A (ja) | 結腸直腸癌におけるｐｏｄｘｌタンパク質 | |
| RU2013125772A (ru) | Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецепторов фолиевой кислоты альфа | |
| RU2015104579A (ru) | Диагностические анализы и наборы для детекции фолатного рецептора 1 | |
| JP2009528507A (ja) | Ｒｅｇ４タンパク質を用いて膵癌を診断する方法 | |
| US20230408521A1 (en) | Gdf-15 as a diagnostic marker for melanoma | |
| JP2016500659A5 (enExample) | ||
| JP2021073437A (ja) | 前立腺がんの分析のための組成物及び方法 | |
| JP5783909B2 (ja) | 悪性腫瘍の診断方法 | |
| JP2015514707A5 (enExample) | ||
| JP2016516008A5 (enExample) | ||
| JP2021535410A (ja) | 全自動化学発光分析装置に基づく血清ｔｋ１検出キット | |
| WO2008035527A1 (fr) | ANTICORPS MONOCLONAL ANTI-C1q | |
| JP7315968B2 (ja) | 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び対象におけるｎａｓｈの検出方法 | |
| JP6276992B2 (ja) | 胸膜中皮腫患者の早期発見のための分子マーカー及びその発現解析方法 | |
| RU2671578C2 (ru) | Способ прогнозирования риска возникновения рака или диагностирования рака у женщины | |
| JP5856956B2 (ja) | 血液検査方法 | |
| RU2013158627A (ru) | Антитела к рецептору человеческого эритропоэтина и способы их применения | |
| JP2018520366A5 (enExample) | ||
| JP7315965B2 (ja) | ウィルス性肝癌の検出方法 |